medigraphic.com
Boletín Médico del Hospital Infantil de México

2013, Número 5

<< Anterior Siguiente >>

Bol Med Hosp Infant Mex 2013; 70 (5)


Retinopatía del prematuro: controversias en el uso de antiangiogénicos intraoculares

Ramírez-Ortiz MA, Lara-Molina C, Villanueva-García D, Villa-Guillén M, Jasso-Gutiérrez L, Padilla-Sierra LC, Robredo-Torres V, Bravo-Ortiz JC, Gutiérrez PJA, Angulo CE, Mancilla RJ, Salgado-Valladares MB, Hernández-Peláez MG, Hernández SL, Orozco GLP, Zepeda-Romero LC

Idioma: Español
Referencias bibliográficas: 47
Paginas: 344-350
Archivo PDF: 64.11 Kb.


RESUMEN

El aumento en la sobrevida de los recién nacidos prematuros, las características del cuidado neonatal y la escasez de programas para la prevención, detección y tratamiento de la retinopatía del prematuro provocan que esta enfermedad sea la principal causa de ceguera infantil prevenible en México.
El advenimiento de agentes antiangiogénicos de uso oncológico, y su uso —no autorizado, aunque con buenos resultados— en el tratamiento de enfermedades vaso proliferativas en la retina del paciente adulto, así como la presencia de reportes anecdóticos en la literatura y series de casos con serias fallas metodológicas han sugerido su utilización en el tratamiento de la retinopatía del prematuro. Desafortunadamente, estos agentes, utilizados indiscriminadamente, presentan absorción sistémica y causan efectos secundarios en el organismo del paciente prematuro. Además, no existen estudios de seguimiento a largo plazo que garanticen la seguridad de su uso en esta población. El presente artículo describe la situación en nuestro país y advierte sobre los riesgos de estos medicamentos en la población de pacientes prematuros.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Secretaría de Salud. Reforma Artículo 61 de la Ley General de Salud. Diario Oficial de la Federación 25 de enero 2013;DCCXII (19, segunda sección):1.

  2. Zepeda-Romero LC, Barrera-de-León JC, Camacho-Choza C, Gonzalez Bernal C, Camarena-García E, Díaz-Alatorre C, et al. Retinopathy of prematurity as a major cause of severe visual impairment and blindness in children in schools for the blind in Guadalajara city, Mexico. Br J Ophthalmol 2011;95:1502-1505.

  3. Kong L, Fry M, Al-Samarraie M, Gilbert C, Steinkuller PG. An update on progress and the changing epidemiology of causes of childhood blindness worldwide. J AAPOS 2012;16: 501-507.

  4. World Health Organization. Born too soon: the Global Action Report on preterm birth. The Partnership for Maternal, Newborn and Child Health. Disponible en: http://www.who.int/pmnch/media/news/2012/preterm_birth_report/en/index.html

  5. Instituto Nacional de Estadística y Geografía. Estadísticas de Natalidad. Disponible en: http://www.inegi.org.mx/est/contenidos/proyectos/registros/vitales/natalidad/default.aspx

  6. Zepeda-Romero LC, Gutiérrez-Padilla JA, De la Fuente-Torres-MA, Angulo-Castellanos E, Ramos Padilla E, Quinn GE. Detection and treatment for retinopathy of prematurity in Mexico: need for effective programs. J AAPOS 2008;12:225-226.

  7. Bradley MH, Motley WW 3rd. Pediatric ophthalmology fellowship training in laser ablation for retinopathy of prematurity. J AAPOS 2012;16:539-542.

  8. Wong RK, Ventura CV, Espiritu MJ, Yonekawa Y, Henchoz L, Chiang MF, et al. Training fellows for retinopathy of prematurity care: a Web-based survey. J AAPOS 2012;16:177-181.

  9. Darlow BA, Ells AL, Gilbert CE, Gole GA, Quinn GE. Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed 2013;98:F170-F174.

  10. US Food and Drug Administration. News and Events. FDA Commissioner announces Avastin decision. Disponible en: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280536.htm.

  11. Harnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med 2012;367:2515-2526.

  12. Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2007;245:1727-1730.

  13. Travassos A, Teixeira S, Ferreira P, Regadas I, Travassos AS, Esperancinha FE, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 2007;38:233-237.

  14. Micieli JA, Surkont M, Smith AF. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am J Ophthalmol 2009;148:536-543.e2.

  15. Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364:603-615.

  16. Good WV, Palmer EA. Bevacizumab for retinopathy of prematurity. N Engl J Med 2011;364:2359; author reply 2361-2362.

  17. Gilbert CE, Zin A, Darlow B. Bevacizumab for retinopathy of prematurity. N Engl J Med 2011;364:2359-2360; author reply 2361-2362.

  18. Lim LS, Mitchell P, Wong TY. Bevacizumab for retinopathy of prematurity. N Engl J Med 2011;364:2360; author reply 2361-2362.

  19. Gole GA, Camuglia JE, Ells AL. Bevacizumab for retinopathy of prematurity. N Engl J Med. 2011;364:2360-2361; author reply 2362.

  20. Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, Salazar-Teran N, Chan RV. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008;28(suppl 3):S19-S25.

  21. Azad R, Dave V, Jalali S. Use of intravitreal anti-VEGF: retinopathy of prematurity surgeons’ in Hamlet’s dilemma? Indian J Ophthalmol 2011;59:421-422.

  22. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.

  23. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.

  24. Hård AL, Hellström A. On the use of antiangiogenetic medications for retinopathy of prematurity. Acta Paediatr 2011;100:1063-1065.

  25. Raizada S, Kandari JA, Sabti KA. Will the BEAT-ROP study results really beat ROP? Invest Ophthalmol Vis Sci 2011;52:9288-9289.

  26. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezza MK, Singh RJ. Pharmakokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179-2182.

  27. Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, et al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial grow factor in infants with retinopathy of prematurity. Am J Ophthalmol 2012;153:327-333.

  28. Orozco-Gómez LP, Hernández-Salazar L, Moguel-Ancheita S, Ramírez-Moreno MA, Morales-Cruz MV. Láser-ranibizumab para tratar retinopatía del prematuro en estadio umbral-preumbral. Tres años de experiencia. Cir Cir 2011;79: 225-232.

  29. Avery RL. Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both? J AAPOS 2012;16:2-4.

  30. Zepeda-Romero LC, Liera-Garcia JA, Gutiérrez-Padilla JA, Valtierra-Santiago CI, Avila-Gómez CD. Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity. Eye 2010;24:931-933.

  31. Jalali S, Balakrishnan D, Zeynalova Z, Padhi TR, Rani PK. Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian Twin Cities Retinopathy of Prematurity Screening database Report number 5. Arch Dis Child Fetal Neonatal Ed 2013;98:F327-F333.

  32. Sharma S, Johnson D, Abouammoh M, Hollands S, Brissette A. Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections. Can J Ophthalmol 2012;47:275-279.

  33. Atchaneeyasakul LO, Trinavarat A. Choroidal ruptures after adjunvant intravitreal injection of bevacizumab for aggressive posterior retinopathy of prematurity. J Perinatol 2010;30: 497-499.

  34. Day S, Acquah K, Mruthyunjaya P, Grossman DS, Lee PP, Sloan FA. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol 2011;152: 266-272.

  35. Goldberg RA, Flynn HW Jr, Isom RF, Miller D, Gonzalez S. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol 2012;153:204-208.e1.

  36. Erinieri JP, Fong AJ, Kemeny NE, Brown KT, Getrajdman GI, Solomon SB. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer 2011;117:1296-1301.

  37. Zhao J, Li H, Zhang L, Zhong W, Li LY, Wen YB, et al. Clinical and pathological analyses of bevacizumab-induced renal impairment in four patients. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2012;34:153-158.

  38. Barber NA, Ganti AK. Pulmonary toxicities from targeted therapies: a review. Target Oncol 2011;6:235-243.

  39. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004;4:361-370.

  40. Gruenewald F., Prota A., Giese A. and Ballmer-Hofer K. Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. Biochim Biophys Acta 2010;1804:567-580.

  41. Machado FG, Kuriki PS, Fujihara CK, Fanelli C, Arias SC; Malheiros DM, et al. Chronic VEFG blockade worsens glomerular injury in the remnant kidney model. PloS One 2012;7:e39580.

  42. Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 2012;130:1000-1006.

  43. Kaiser PK, Cruess AF, Bogaert P, Khunti K, Kelly SP. Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines. Graefes Arch Clin Exp Ophthalmol 2012;250:1563-1571.

  44. Ophthalmic Mutual Insurance Company: A Risk Retention Group. Anti-VEGF intravitreal injections for ROP: risk management analysis and recommendations. Disponible en: http://www.omic.com/rop-intravitreal-anti-vegf-injections-ris-management-recommendations/

  45. Dobson V, Quinn GE, Summers CG, Hardy RJ, Tung B; Cryotherapy for Retinopathy of Prematurity Cooperative Group. Visual acuity at 10 years in Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) study eyes: effect of retinal residua of retinopathy of prematurity. Arch Ophthalmol 2006;124:199-202.

  46. Phelps DL; ETROP Cooperative Group. The Early Treatment for Retinopathy of Prematurity study: better outcomes, changing strategy. Pediatrics 2004;114:490-491.

  47. Wiles JR, Vinks AA, Akinbi H. Federal legislation and the advancement of neonatal drug studies. J Pediatr 2013;162:12-15.




2020     |     www.medigraphic.com